secwatch.observer — SEC 8-K summary
======================================

Issuer:     ADMA BIOLOGICS, INC. (ADMA)
CIK:        0001368514
Form:       8-K
Filed at:   2023-03-23T23:59:59+00:00
Accession:  0001140361-23-013402
Event type: earnings
Sentiment:  positive
Materiality: 0.78
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ADMA Q4 revenue $50M (+90% YoY); FY 2023 guidance >$210M, first-time EBITDA in H2 2023
--------------------------------------------------------------------------------

- Q4 2022 total revenues $50.0M (+90% YoY); gross profit $14.2M (vs $3.5M); net loss $12.2M ($0.06 loss per share).
- Full year 2022 revenues $154.1M (+90% YoY); net loss $65.9M (improved from $71.6M).
- FY 2023 total revenue expected to exceed $210M; first-time positive EBITDA no later than second half 2023.
- 2024-2025 revenue targets: $250M+ in 2024, $300M+ thereafter; gross margins 40-50%, net income margins 20-30%.
- ASCENIV production to expand to 4,400L scale; BioCenters on track for 10 FDA-licensed sites by year-end 2023; strategic review continues with Morgan Stanley.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1368514/000114036123013402/0001140361-23-013402-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1368514/000114036123013402/brhc10050204_8-k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-23-013402

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer